NASDAQ:ATRA Atara Biotherapeutics (ATRA) Stock Price, News & Analysis → SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad) Free ATRA Stock Alerts $0.66 -0.03 (-4.34%) (As of 04/19/2024 ET) Add Compare Share Share Today's Range$0.64▼$0.7150-Day Range$0.60▼$0.8452-Week Range$0.20▼$3.06Volume1.63 million shsAverage Volume2.77 million shsMarket Capitalization$78.90 millionP/E RatioN/ADividend YieldN/APrice Target$28.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Atara Biotherapeutics alerts: Email Address Atara Biotherapeutics MarketRank™ Stock AnalysisAnalyst RatingHold2.00 Rating ScoreUpside/Downside4,136.0% Upside$28.00 Price TargetShort InterestBearish9.41% of Shares Sold ShortDividend StrengthN/ASustainability-0.87Upright™ Environmental ScoreNews SentimentN/AInsider TradingSelling Shares$25,625 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.30) to ($0.31) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.74 out of 5 starsMedical Sector204th out of 911 stocksBiological Products, Except Diagnostic Industry22nd out of 148 stocks 3.0 Analyst's Opinion Consensus RatingAtara Biotherapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageAtara Biotherapeutics has received no research coverage in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted9.41% of the outstanding shares of Atara Biotherapeutics have been sold short.Short Interest Ratio / Days to CoverAtara Biotherapeutics has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Atara Biotherapeutics has recently increased by 1.81%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldAtara Biotherapeutics does not currently pay a dividend.Dividend GrowthAtara Biotherapeutics does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAtara Biotherapeutics has received a 75.69% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for cancer", "Clinical research services for physiological diseases ", and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Atara Biotherapeutics is -0.87. Previous Next 2.0 News and Social Media Coverage News SentimentAtara Biotherapeutics has a news sentiment score of 0.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Atara Biotherapeutics this week, compared to 1 article on an average week.Search InterestOnly 11 people have searched for ATRA on MarketBeat in the last 30 days. This is a decrease of -15% compared to the previous 30 days.MarketBeat Follows9 people have added Atara Biotherapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 80% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Atara Biotherapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $25,625.00 in company stock.Percentage Held by InsidersOnly 4.50% of the stock of Atara Biotherapeutics is held by insiders.Percentage Held by Institutions70.90% of the stock of Atara Biotherapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Atara Biotherapeutics are expected to grow in the coming year, from ($1.30) to ($0.31) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Atara Biotherapeutics is -0.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Atara Biotherapeutics is -0.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad AltimetrySecret Bull Market Starts in This Unusual Sector"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch. Click for my No. 1 investment, all free of charge, click here. About Atara Biotherapeutics Stock (NASDAQ:ATRA)Atara Biotherapeutics, Inc. develops therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA2271 and ATA3271 to treat mesothelin; and ATA3219 for the treatment of B-cell malignancies, as well as ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center. The company was incorporated in 2012 and is headquartered in Thousand Oaks, California.Read More ATRA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ATRA Stock News HeadlinesApril 18, 2024 | americanbankingnews.comAtara Biotherapeutics (NASDAQ:ATRA) Stock Price Crosses Below 50-Day Moving Average of $0.73April 5, 2024 | businesswire.comAtara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)April 20, 2024 | Altimetry (Ad)Secret Bull Market Starts in This Unusual Sector"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch. April 1, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Atara Biotherapeutics (ATRA) and Embecta Corporation (EMBC)March 28, 2024 | investorplace.comATRA Stock Earnings: Atara Biotherapeutics Misses EPS, Misses Revenue for Q4 2023March 28, 2024 | benzinga.comAtara Biotherapeutics: Q4 Earnings InsightsMarch 28, 2024 | finance.yahoo.comAtara Biotherapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Operational ProgressMarch 16, 2024 | finance.yahoo.comATRA Apr 2024 0.500 callApril 20, 2024 | Altimetry (Ad)Secret Bull Market Starts in This Unusual Sector"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch. February 29, 2024 | msn.comFDA clears Atara to begin Phase 1 study for lupus nephritis drugFebruary 29, 2024 | marketwatch.comAtara Biotherapeutics Gets FDA Clearance for ATA3219 IND ApplicationFebruary 29, 2024 | finance.yahoo.comAtara Biotherapeutics Receives FDA Clearance of IND Application in Lupus Nephritis for ATA3219, an Allogeneic CAR T TherapyFebruary 28, 2024 | finance.yahoo.comAtara Biotherapeutics to Participate in Cell Therapy Panel Discussion at the Cowen 44th Annual Health Care ConferenceFebruary 14, 2024 | finance.yahoo.comAtara Biotherapeutics Announces Submission of Investigational New Drug Application for ATA3219 for Treatment of Lupus NephritisFebruary 14, 2024 | businesswire.comAtara Biotherapeutics Announces Submission of Investigational New Drug Application for ATA3219 for Treatment of Lupus NephritisFebruary 9, 2024 | uk.investing.comAtara Biotherapeutics Inc (ATRA)February 6, 2024 | uk.finance.yahoo.comAtara Biotherapeutics, Inc. (0HIY.L)February 5, 2024 | seekingalpha.comAtara Biotherapeutics: Opportunity As They Sell Off Their Approved Asset For Longer RunwayFebruary 3, 2024 | finance.yahoo.comAfter losing 76% in the past year, Atara Biotherapeutics, Inc. (NASDAQ:ATRA) institutional owners must be relieved by the recent gainJanuary 11, 2024 | finance.yahoo.comSeth Klarman's Firm Exits Atara Biotherapeutics Inc HoldingJanuary 11, 2024 | finance.yahoo.comSeth Klarman's Exit from Atara Biotherapeutics IncJanuary 9, 2024 | businesswire.comTab-cel BLA on Track for Submission in Q2 2024 Following Positive New Data from Pivotal ALLELE StudyJanuary 8, 2024 | msn.comAtara to conduct $15M registered direct offeringJanuary 8, 2024 | finance.yahoo.comAtara Biotherapeutics Announces $15 Million Registered Direct OfferingJanuary 8, 2024 | finance.yahoo.comAtara Biotherapeutics to Present Recent Progress and Key Upcoming Milestones at the 42nd Annual J.P. Morgan Healthcare ConferenceJanuary 4, 2024 | finance.yahoo.comAtara Biotherapeutics to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceDecember 20, 2023 | finance.yahoo.comAtara Biotherapeutics Announces Closing of Expanded Global Tab-cel® Partnership with Pierre Fabre LaboratoriesSee More Headlines Receive ATRA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Atara Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/01/2023Today4/19/2024Next Earnings (Estimated)5/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:ATRA CUSIPN/A CIK1604464 Webwww.atarabio.com Phone(805) 623-4211FaxN/AEmployees334Year FoundedN/APrice Target and Rating Average Stock Price Target$28.00 High Stock Price Target$28.00 Low Stock Price Target$28.00 Potential Upside/Downside+4,136.0%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($2.62) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-276,130,000.00 Net Margins-3,220.88% Pretax Margin-3,220.71% Return on Equity-783.31% Return on Assets-122.34% Debt Debt-to-Equity RatioN/A Current Ratio0.72 Quick Ratio0.65 Sales & Book Value Annual Sales$8.57 million Price / Sales9.21 Cash FlowN/A Price / Cash FlowN/A Book Value($0.97) per share Price / Book-0.68Miscellaneous Outstanding Shares119,360,000Free Float113,988,000Market Cap$78.90 million OptionableOptionable Beta0.69 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesDr. Pascal Touchon D.V.M. (Age 61)President, CEO & Director Comp: $1.08MMr. K. Amar Murugan (Age 48)Executive VP & Chief Legal Officer Comp: $618.52kMr. Eric Hyllengren (Age 48)Executive VP & Chief Financial Officer Dr. Anhco Nguyen Ph.D. (Age 51)Executive VP and Chief Scientific & Technical Officer Alex ChapmanVice President of Corporate Communications & Investor RelationsMs. Jill Henrich (Age 61)Executive VP and Global Head of Regulatory Affairs & Quality Mr. Dan MaziaszExecutive VP & Chief Business OfficerMs. Rajani Dinavahi M.D.Senior VP & Chief Medical OfficerMore ExecutivesKey CompetitorsAthira PharmaNASDAQ:ATHACEL-SCINYSE:CVMProtalix BioTherapeuticsNYSE:PLXAlloVirNASDAQ:ALVRPassage BioNASDAQ:PASGView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 80,110 shares on 3/11/2024Ownership: 6.560%Pascal TouchonSold 24,844 sharesTotal: $17,887.68 ($0.72/share)Anhco NguyenSold 10,746 sharesTotal: $7,737.12 ($0.72/share)Goldman Sachs Group Inc.Sold 3,542,220 shares on 3/1/2024Ownership: 0.571%GSA Capital Partners LLPBought 784,367 shares on 2/16/2024Ownership: 0.770%View All Insider TransactionsView All Institutional Transactions ATRA Stock Analysis - Frequently Asked Questions Should I buy or sell Atara Biotherapeutics stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Atara Biotherapeutics in the last twelve months. There are currently 3 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" ATRA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ATRA, but not buy additional shares or sell existing shares. View ATRA analyst ratings or view top-rated stocks. What is Atara Biotherapeutics' stock price target for 2024? 3 brokerages have issued 12 month price objectives for Atara Biotherapeutics' shares. Their ATRA share price targets range from $28.00 to $28.00. On average, they predict the company's share price to reach $28.00 in the next twelve months. This suggests a possible upside of 4,136.0% from the stock's current price. View analysts price targets for ATRA or view top-rated stocks among Wall Street analysts. How have ATRA shares performed in 2024? Atara Biotherapeutics' stock was trading at $0.5128 at the start of the year. Since then, ATRA stock has increased by 28.9% and is now trading at $0.6610. View the best growth stocks for 2024 here. When is Atara Biotherapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024. View our ATRA earnings forecast. How were Atara Biotherapeutics' earnings last quarter? Atara Biotherapeutics, Inc. (NASDAQ:ATRA) issued its quarterly earnings data on Thursday, March, 28th. The biotechnology company reported ($0.56) earnings per share for the quarter, topping the consensus estimate of ($0.61) by $0.05. The biotechnology company had revenue of $4.25 million for the quarter, compared to analyst estimates of $2.45 million. Atara Biotherapeutics had a negative net margin of 3,220.88% and a negative trailing twelve-month return on equity of 783.31%. What is Pascal Touchon's approval rating as Atara Biotherapeutics' CEO? 38 employees have rated Atara Biotherapeutics Chief Executive Officer Pascal Touchon on Glassdoor.com. Pascal Touchon has an approval rating of 60% among the company's employees. This puts Pascal Touchon in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. 88.0% of employees surveyed would recommend working at Atara Biotherapeutics to a friend. What other stocks do shareholders of Atara Biotherapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Atara Biotherapeutics investors own include CRISPR Therapeutics (CRSP), AbbVie (ABBV), Exelixis (EXEL), Dynavax Technologies (DVAX), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), OPKO Health (OPK), Gilead Sciences (GILD), Micron Technology (MU) and Pfizer (PFE). How do I buy shares of Atara Biotherapeutics? Shares of ATRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ATRA) was last updated on 4/20/2024 by MarketBeat.com Staff From Our PartnersThe “Perfect Storm” for GoldGold Safe ExchangeBiden’s $374B Giveaway Into This SectorDTISHOCKING Crypto Leak…Crypto 101 MediaYour Money is Not SafeAmerican AlternativeThe #1 Crypto for 2024InvestorPlaceDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsUrgent alert: open this for a huge profit potentialTimothy SykesTiny Biotech Stock Wins $75 Billion PatentBehind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Atara Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.